- 2005: re-integration of the Diosynth activities into Organon.
- 2007: acquisition of Organon Biosciences by Schering-Plough
- 2009: merger of Merck & Co. and Schering-Plough.
- 2013: acquisition of API activities by Aspen Pharmacare (South-Africa)
Although we have undergone these organizational changes, our activities have not changed. We continue to focus on producing high quality Active Ingredients for our own use as well as for our customers' use.
Traditionally, our main therapeutic areas have been women's health (contraception and fertility), anesthesia and neuroscience, as these were the therapeutic areas of interest to former Organon. Additionally, we have the capabilities to produce a number of Active Ingredients specifically for our external customers. For more detailed information on our products, please see the chapter 'Products'.